Clinical effects of valsartan and irbesartan on diabetic nephropathy with hypertension
Li Guanjin
Abstract：Objective To compare the effects of valsartan and irbesartan on diabetic nephropathy (DN) with hypertension.Methods Totally 162 patients with DN accompanied by hypertension from March 2016 to March 2017 in Beijing Puren Hospital were randomly divided into observation group and control group,with 81 cases in each group.On the basis of conventional basic treatment,the control group took valsartan capsules and the observation group took irbesartan tablets for 3 courses(1 course =12 weeks).Results Systolic blood pressure and urinary microalbumin level significantly decreased 6,9 months after treatment compared to those before treatment in observation group[(130 ± 11),(129 ± 13) mmHg vs (163 ±7)mmHg;26(18,62),13(7,31)mg/L vs 47(31,98) mg/L] (P ＜ 0.05).Urinary microalbumin level significantly decreased 6,9 months after treatment compared to that before treatment in control group [33 (19,49),18 (7,33) mg/L vs 52 (41,119) mg/L] (P ＞ 0.05).Blood pressure and urinary microalbumin level showed no significant differences between groups before and 3,6,9 months after treatment (P ＞ 0.05).Levels of total cholesterol,triacylglycerol,serum creatinine and glycosylated hemoglobin had no significant differences between groups before and after treatment(P ＞0.05).The total effective rate in observation group was significantly higher than that in control group [92.6％ (75/81) vs 61.7％ (50/81)] (P =0.016).There was no severe adverse reaction occurred in both groups.Conclusion Irbesartan and valsartan treating DN with hypertension can effectively reduce urinary microalbumin level;irbesartan is more effective in lowering systolic blood pressure;both drugs have good clinical safety.
Keywords：Diabetic nephropathyHypertensionIrbesartanValsartan
Publication Date：2017-12-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1831-1834 )